BerGenBio

Share Issue/Capital Change • Jun 27, 2017

BerGenBio ASA: Exercise of employee share options and increase of share capital

BerGenBio ASA: Exercise of employee share options and increase of share capital

Bergen, Norway, 27 June 2017.

Participants in BerGenBio ASA's (the "Company") (OSE: BGBIO) employee share

option program, not being primary insiders, have exercised a total number of

15,000 options with a strike price of NOK 10.6172. Each option gives the right

to receive one share in the Company.

The Board of Directors of the Company has, to fulfil the Company's obligations

under the option agreements, resolved to increase the Company's share capital by

NOK 1,500 through the issuance of 15,000 new shares, each with a nominal value

of NOK 0.10, against payment of a total subscription price of NOK 159,258.

Subsequent to the issuance of the new shares, the Company's share capital will

be NOK 4,975,720 divided into 49,757,200 shares, each with a nominal value of

NOK 0.10.

For further information, please contact:

Richard Godfrey, Chief Executive Officer

Phone: +47 917 86 304

E-mail: media@bergenbio.com

About BerGenBio ASA

BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused

on developing a pipeline of first-in-class AXL kinase inhibitors to treat

multiple cancer indications. The Company is a world leader in understanding the

central role of AXL kinase in promoting cancer spread, immune evasion and drug

resistance in multiple aggressive haematological and solid cancers.

BGB324, is a selective, potent and orally available small molecule AXL inhibitor

in Phase II clinical development in four major cancer indications. It is the

only selective oral AXL inhibitor in clinical development. BGB324 is being

developed by BerGenBio as a single agent therapy in acute myeloid leukaemia

(AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA®

(erlotinib) in advanced non-small-cell lung cancer (NSCLC): and in combination

with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast

cancer (TNBC) in collaboration with MSD.

The Company is also developing a diversified pre-clinical pipeline of selective

AXL inhibitors including BGB149, anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.